Table 1. Description of include studies.
| Study | Location | Disease | Stage | Median follow-up (months) | Sample size | Number of cycles | Use of G-CSF | |||
|---|---|---|---|---|---|---|---|---|---|---|
| RCHOP-14/RCHOP-21 | RCHOP-14/RCHOP-21 | RCHOP-14 | RCHOP-21 | |||||||
| Cunningham 2013 (14) | UK | DLBCL | I–IV | 46 | 540/540 | 6 plus 2 R/8 | Given to all patients | 54% of patients | ||
| Delarue 2013 (15) | France, Belgium, Switzer, Portugal | DLBCL | I–IV | 56 | 304/298 | 8/8 | 90% of patients, decision of the treating physician | 74% of patients, decision of the treating physician | ||
| Gleeson 2016 (21) | UK | DLBCL | I–II | 86.4 | 22/28 | 6 plus 2 R/8 | Given to all patients | 54% of patients | ||
| Payandeh 2016 (17) | Iran | B-cell NHL | III–IV | 45 | 66/77 | 6–8/6–8 | Given to all patients | At the desertion of the treating physician | ||
| Watanabe 2018 (16) | Japan | Untreated advanced-stage FL | III–IV | 134.4 | 151/149 | 6/6 | Given to all patients | At the desertion of the treating physician | ||
| Li 2019 (18) | China | DLBCL | I–IV | 45.6 | 349/353 | 6–8/6–8 | Given to all patients | The investigator’s discretion | ||
| Wästerlid 2017 (20)* | Swedish | PMBL | I–IV | 47.4 | 1196/910 | 6/6 | Not report | Not report | ||
| Knauf 2019 (19)* | German | DLBCL | I–IV | 60 | 264/318 | 6/6 | 73% of patients use it at least once | 48.7% of patients use it at least once | ||
*, OCSs. G-CSF, granulocyte colony-stimulating factor; RCHOP, rituximab combined with cyclophosphamide, doxorubicin, vincristine, and prednisolone; DLBCL, diffuse large B-cell lymphoma; PMBL, primary mediastinal B-cell lymphoma; FL, follicular lymphoma; R, rituximab; OCSs, observational comparative studies.